FR3109089B1 - Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales - Google Patents
Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales Download PDFInfo
- Publication number
- FR3109089B1 FR3109089B1 FR2003496A FR2003496A FR3109089B1 FR 3109089 B1 FR3109089 B1 FR 3109089B1 FR 2003496 A FR2003496 A FR 2003496A FR 2003496 A FR2003496 A FR 2003496A FR 3109089 B1 FR3109089 B1 FR 3109089B1
- Authority
- FR
- France
- Prior art keywords
- pharmaceutical composition
- treatment
- inflammatory bowel
- bowel diseases
- vorapaxar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 239000011247 coating layer Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 abstract 2
- 229960005044 vorapaxar Drugs 0.000 abstract 2
- QWKAUGRRIXBIPO-UHFFFAOYSA-N Atopaxar Chemical class N=C1C=2C(F)=C(OCC)C(OCC)=CC=2CN1CC(=O)C(C=C(C=1OC)C(C)(C)C)=CC=1N1CCOCC1 QWKAUGRRIXBIPO-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229950007648 atopaxar Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L’invention concerne une composition pharmaceutique convenant à une administration par voie orale, contenant en tant que principe actif un composé choisi dans le groupe constitué du vorapaxar, des isomères du vorapaxar, de l’atopaxar, de la 3-2-(chloro-phényl)-1-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propénone et de leurs sels pharmaceutiquement acceptables. Cette composition contient des particules comprenant un cœur contenant un mélange du principe actif et d’une substance apte à inhiber la recristallisation du principe actif à un pH devient supérieur ou égal à 5 ; et une couche d’enrobage à libération contrôlée pH-dépendante recouvrant ledit cœur, ladite couche d’enrobage étant formée d’un agent d’enrobage gastro-résistant et étant poreuse.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2003496A FR3109089B1 (fr) | 2020-04-08 | 2020-04-08 | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
| EP21715934.2A EP4132473A1 (fr) | 2020-04-08 | 2021-04-07 | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
| PCT/EP2021/059076 WO2021204883A1 (fr) | 2020-04-08 | 2021-04-07 | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2003496 | 2020-04-08 | ||
| FR2003496A FR3109089B1 (fr) | 2020-04-08 | 2020-04-08 | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3109089A1 FR3109089A1 (fr) | 2021-10-15 |
| FR3109089B1 true FR3109089B1 (fr) | 2023-04-14 |
Family
ID=71662038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2003496A Active FR3109089B1 (fr) | 2020-04-08 | 2020-04-08 | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4132473A1 (fr) |
| FR (1) | FR3109089B1 (fr) |
| WO (1) | WO2021204883A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3134314A1 (fr) | 2022-04-08 | 2023-10-13 | Cvasthera | Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2065384T1 (sl) | 2002-04-16 | 2011-05-31 | Schering Corp | Tricikliäśni trombin receptor antagonist |
| US20120100214A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Sustained-Release Tablet and Process for Preparing the Same |
| FR3014693B1 (fr) * | 2013-12-16 | 2016-01-08 | Pf Medicament | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
| CN105919966A (zh) * | 2016-06-12 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种硫酸沃拉帕沙制剂及其应用 |
-
2020
- 2020-04-08 FR FR2003496A patent/FR3109089B1/fr active Active
-
2021
- 2021-04-07 WO PCT/EP2021/059076 patent/WO2021204883A1/fr unknown
- 2021-04-07 EP EP21715934.2A patent/EP4132473A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021204883A1 (fr) | 2021-10-14 |
| FR3109089A1 (fr) | 2021-10-15 |
| EP4132473A1 (fr) | 2023-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1945209B1 (fr) | Composés antibactériens à large spectre | |
| JP5933258B2 (ja) | ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物 | |
| JP2008515913A (ja) | 多発性嚢胞腎の治療のための方法 | |
| JP2008505913A (ja) | 新規化合物およびこれらの標的に関する組成物ならびに方法 | |
| CN101360738A (zh) | 调节门控离子通道的组合物和方法 | |
| FR2392667A1 (fr) | Composition pharmaceutique a liberation etalee comprenant du propranolol | |
| KR20120104200A (ko) | Ｃｎｓ 장애의 치료를 위한 8에틸6(아릴）피리도［2,3ｄ］피리미딘7（8ｈ）온 | |
| WO2009105234A2 (fr) | Procédés et compositions pour le traitement de troubles associés à des défauts du gène ou de la protéine du régulateur de la conductance transmembranaire d'une fibrose kystique | |
| WO1999064011A1 (fr) | Medicaments | |
| KR20140096098A (ko) | 세포 증식성 장애의 치료를 위한 pak 억제제 | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| WO2018133862A1 (fr) | Utilisation d'un inhibiteur du complexe cytochrome bc1 dans la préparation d'une composition pharmaceutique | |
| KR20070036171A (ko) | 선택적 노르아드레날린 재흡수 억제제와 ｐｄｅｖ 억제제의조합물 | |
| JP5898061B2 (ja) | 細菌のｉｉｉ型分泌系の阻害剤 | |
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| FR3109089B1 (fr) | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales | |
| HUE032235T2 (en) | Azetidinyloxyphenylpyrrolidone compounds | |
| JP2023113705A (ja) | 細胞寿命及び健康寿命を延長するための反応性γ－ケトアルデヒドのスカベンジャーの使用 | |
| Yılmaz et al. | Pharmaco-molecular assessment of the effects of anandamide and its antagonists on hippocampal tissue in Wistar albino rats | |
| EP3573957B1 (fr) | Compositions et procédés de blocage de canaux sodiques | |
| KR20210087532A (ko) | 중추신경계 질환, 당뇨병 및 이의 합병증의 예방 및 치료를 위한 벤즈이미다졸 또는 벤족사졸 유도체 | |
| WO2016135138A1 (fr) | Dérivés d'oxoquinoléine en tant qu'inhibiteurs de mth1 pour la thérapie du cancer | |
| EA010868B1 (ru) | Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций | |
| KR20220035156A (ko) | 베리누라드를 포함하는 과량 방출 저항성 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20211015 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |